Skip to main content
. 2022 Nov 17;12(11):1131. doi: 10.3390/metabo12111131

Figure 6.

Figure 6

Immunoreactivity of Prdm16/Ucp1 proteins after the inhibition of miR-133a expression. (A) The expression levels of miR-133a in fully differentiated adipocytes treated with 5-aza and transfected with or without miR-133a inhibitor. (B–M) Increased immunoreactivity of Prdm16 (green) and Ucp1 (red) in fully differentiated adipocytes treated with 5-aza and transfected with or without miR-133a inhibitor (n = 3/group; blue, DAPI). (N,O) Expression of Prdm16 and Ucp1 in fully differentiated adipocytes treated with 5-aza and transfected with or without miR-133a inhibitor using Western blotting. (P,Q) Quantified changes in Prdm16 and Ucp1 in fully differentiated adipocytes treated with 5-aza and transfected with or without miR-133a inhibitor. (R,S) Normalized intensity of Prdm16 and Ucp1 relative to GAPDH, presented as the mean ± SD (n= 3). * p < 0.05, ** p < 0.01, *** p < 0.001 compared with the control group; # p < 0.05, ## p < 0.01 compared with other groups; bar = 130 μm. Prdm16, PR domain containing 16; Ucp-1, uncoupling protein-1; miR-133a, microRNA-133a; 5-aza-dC, 5-aza-2′-deoxycytidine.